What Is in Store for Allergan? | Market Checkup - 4/29/14 | The Motley Fool

TL;DR

Analysis of healthcare stocks, including AMICUS and Biota, with potential mergers like Valiant and Allergan.

Transcript

hi fools welcome to market checkup The Motley Fool's healthcare focused investing show I'm David Williamson and i'm joined as usual by michael douglas great to have you Michael on this rainy nasty Tuesday but we have a great show for you out there so I hope everyone is excited we have more earnings as usual and more MA which is really what we do an... Read More

Key Insights

• 🛀 AMICUS shows promising results in a fabry disease drug trial.
• 😳 Biota faces a setback with a halt on its flu drug development.
• 💇 Merck struggles with revenue but shows strength in cost-cutting measures.
• 💪 Sanofi maintains stability through strong emerging market presence and a robust drug pipeline.
• 😀 Allergan faces potential takeover by Valiant, triggering speculations of mergers with companies like Shire or Johnson & Johnson.
• 👨‍💼 Consider investing in healthcare stocks based on underlying business strength rather than temporary market chaos.

Questions & Answers

Q: What were the positive results reported by AMICUS from the phase three clinical trial?

AMICUS reported positive results for a fabry disease drug, showing stable kidney function and safety over 18-24 months.

Q: What led to the decrease in Biota's shares by 30%?

Biota faced a halt on their flu drug by the US Office of Biomedical Advanced Research and Development Authority.

Q: How did Merck fare in its Q1 2014 earnings report?

Merck missed on revenue but beat on EPS due to cost cutting and restructuring, following challenges like generic competition.

Q: Why is Sanofi considered stable despite missing revenue estimates in its quarterly report?

Sanofi's strong performance in emerging markets and a promising pipeline of drugs like Lantus U300 and Alirocumab contribute to its stability.

Summary & Key Takeaways

• Market Checkup show discussing healthcare stocks like AMICUS and Biota.

• AMICUS reports positive results from a phase three clinical trial for a fabry disease drug.

• Biota's shares fall by 30% due to a halt on a flu drug by the US Office of Biomedical Advanced Research and Development Authority.